sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY July 2012 Issue | Archived Issues

Upcoming CME conferences

State-of-the-Art Spine Care 2012 – Sept. 29

Multi-Specialty Plastic Surgery Symposium and the Bernard G. Sarnat, MD, Lectureship – Nov. 2-4

20th International Symposium on Pancreatic & Biliary Endoscopy Conference – Jan. 25-27


Grand rounds

Click here to view upcoming grand rounds.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Restricted distribution programs required for bosentan, ambrisentan

June Pharmacy and Therapeutics decisions released

Due to the risk of teratogenicity associated with bosentan and ambrisentan, manufacturers of both drugs require that prescribers and patients be enrolled in restricted distribution programs. Please note that bosentan and ambrisentan are non-formulary at Cedars-Sinai.

If continuation of therapy is warranted for a patient who was on bosentan/ambrisentan prior to admission, please refer to the procedure outlined in the PDF below.

Bostentan Ambrisentan MD Fact Sheet - July 2012 (PDF)

In other pharmacy news, the June Pharmacy and Therapeutics Committee decisions and pertinent agenda topics are summarized in the PDF below. Highlights include: 2012 chest updates, anticoagulation protocol updates for dalteparin and enoxaparin, and 2012 empiric treatment guidelines for common adult and pediatric infections.

P&T Decisions - June 2012 (PDF)